SAN JOSE, Calif. & JERUSALEM — Accellix, Inc., the leading sample to answer flow cytometry GMP platform company, is pleased to announce the appointment of Greg Hamilton as Chief Executive Officer and member of the Board effective September 23, 2024. He brings over 25 years of management experience in molecular diagnostics, life science tools, manufacturing […]
Press Releases
Accellix Appoints Greg Hamilton as Chief Executive Officer as Company Accelerates Growth in Cell Therapy and Blood Bank Markets
September 23, 2024 | 3 min read
Accellix Raises $10 Million From BroadOak Capital Partners
December 13, 2021 | 3 min read
Accellix will use the investment to expand its commercial resources and infrastructure in support of its cell therapy customers SAN JOSE, Calif. & BETHESDA, Md. — Accellix Inc., which provides quick and accurate flow cytometry results in a compact and easy-to-use platform designed for use by cell therapy companies on the manufacturing floor and at […]
Accellix Expands its Leadership Team
May 11, 2021 | 3 min read
SAN JOSE, Calif. & JERUSALEM — Accellix Inc. is pleased to announce that Terrance Gin is joining its leadership team as Vice President Global Operations effective immediately. Terrance brings over 30 years of management experience in IVD manufacturing, process and product development, clinical laboratory operations, quality assurance, capital improvement, facility, and EH&S. He was VP […]
bioMérieux signs agreement with Accellix, for the Asia Pacific region
May 5, 2021 | 5 min read
bioMérieux strengthens its Quality Control Offering in Advanced Therapy Medicinal Products (ATMP) Marcy-l’Étoile, France and San Jose, California — bioMérieux is designated as the exclusive distributor of Accellix products in China, Japan, Australia and South Korea. Under the agreement signed on February 18th, 2021, bioMérieux will perform the full range of sales, supply and service […]
Accellix, the Cell Therapy QC company raises $9.5 million Series D round
June 11, 2020 | 2 min read
SAN JOSE, Calif. & JERUSALEM — Today Accellix, the Cell Therapy QC company, announced a Series D financing round of $9.5 million led by bioMérieux, a world leader in the field of in vitro diagnostics for over 55 years. All existing major investors participated in this raise and have also agreed to convert their pre-existing […]
Announcing the Next Generation Accellix Instrument and Consumable
April 29, 2020 | 2 min read
Further Simplifying and Automating the QC Workflow in Cell Therapy Manufacturing SAN JOSE, Calif. & JERUSALEM — Accellix, Inc. is launching its Next Generation Integrated Accellix Instrument and Consumables to further automate, simplify and improve reproducibility during the intricate process of QC for cell therapy manufacturing. Accellix entered the cell therapy market in 2017, automating […]
Nir Nimrodi Appointed as Chairman and Chief Executive Officer
January 15, 2020 | 3 min read
Nimrodi Will Lead the Company’s Accelerated Growth as It Launches Custom and Standardized Panel Assays to Be Used by Its Expanding Installed Base. SAN JOSE, Calif. & JERUSALEM — Accellix, Inc. is pleased to announce the appointment of Nir Nimrodi as Chairman and Chief Executive Officer effective immediately. Mr. Nimrodi has served as the Executive […]
Charles Piazza Appointed to Accellix Board of Directors
August 14, 2019 | 2 min read
SAN JOSE, Calif. — Accellix Inc. announces the appointment of a new Board Member, Mr. Charles Piazza. Charles (Chuck) Piazza, Accellix’s newest board member, has over 35 years of global experience within the life science industry serving the pharmaceutical, biotechnology and medical research sectors. His recent positions included Vice President and General Manager for the […]
Accellix Expands Leadership Team and Announces Name Change
July 25, 2019 | 1 min read
SAN JOSE, Calif. & JERUSALEM — LeukoDx, Inc. (“the Company”), is pleased to announce the official name change to Accellix, Inc. (“Accellix”) effective immediately. “The cell therapy market needs a new testing paradigm that can deliver rapid results, and one that can scale to meet the expanding adoption of therapy regimens. The
